Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - montelukast sodium, quantity: 5.2 mg (equivalent: montelukast, qty 5 mg) - tablet, chewable - excipient ingredients: hyprolose; microcrystalline cellulose; iron oxide red; aspartame; magnesium stearate; mannitol; croscarmellose sodium; flavour - -prophylaxis and treatment of chronic asthma in children 2 years to 14 years of of age.,-symptomatic treatment of seasonal allergic rhinitis in children 2 years to 14 years of of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - montelukast sodium, quantity: 5.2 mg (equivalent: montelukast, qty 5 mg) - tablet, chewable - excipient ingredients: iron oxide red; croscarmellose sodium; hyprolose; aspartame; microcrystalline cellulose; mannitol; magnesium stearate; flavour - -prophylaxis and treatment of chronic asthma in children 2 years to 14 years of of age.,-symptomatic treatment of seasonal allergic rhinitis in children 2 years to 14 years of of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - montelukast sodium, quantity: 5.2 mg (equivalent: montelukast, qty 5 mg) - tablet, chewable - excipient ingredients: magnesium stearate; microcrystalline cellulose; mannitol; aspartame; croscarmellose sodium; iron oxide red; flavour - prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. symptomatic treatment of seasonal allergic rhinitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - montelukast sodium, quantity: 5.2 mg (equivalent: montelukast, qty 5 mg) - tablet, chewable - excipient ingredients: microcrystalline cellulose; mannitol; aspartame; croscarmellose sodium; magnesium stearate; iron oxide red; flavour - prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. symptomatic treatment of seasonal allergic rhinitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

torrent australasia pty ltd - montelukast sodium, quantity: 5.2 mg (equivalent: montelukast, qty 5 mg) - tablet, chewable - excipient ingredients: mannitol; magnesium stearate; croscarmellose sodium; aspartame; microcrystalline cellulose; iron oxide red; flavour - prophylaxis and treatment of chronic asthma in adults and children 2 years of age and older. symptomatic treatment of seasonal allergic rhinitis.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - montelukast sodium 5.19mg equivalent to montelukast 5 mg - chewable tablet - 5 mg - active: montelukast sodium 5.19mg equivalent to montelukast 5 mg excipient: aspartame cherry flavour 501027 ap0551 colloidal silicon dioxide croscarmellose sodium stear-o-wet m mannitol microcrystalline cellulose - indicated in paediatric patients 6 to 14 years of age for the relief of daytime and night-time symptoms of seasonal allergic rhinitis and perennial allergic rhinitis.

United States - English - NLM (National Library of Medicine)

sandoz inc - montelukast sodium (unii: u1o3j18sfl) (montelukast - unii:mhm278sd3e) - montelukast 10 mg - montelukast sodium is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 2 years of age and older. montelukast sodium is indicated for prevention of exercise-induced bronchoconstriction (eib) in patients 6 years of age and older. montelukast sodium is indicated for the relief of symptoms of seasonal allergic rhinitis in patients 2 years of age and older and perennial allergic rhinitis in patients 2 years of age and older. because the benefits of montelukast sodium may not outweigh the risk of neuropsychiatric symptoms in patients with allergic rhinitis [see warnings and precautions ( 5.1)] , reserve use for patients who have an inadequate response or intolerance to alternative therapies. montelukast sodium is not indicated for the treatment of an acute asthma attack. montelukast sodium is contraindicated in patients with hypersensitivity to any of its components. risk summary available data from published prospective and retrospective cohort studies over decades w

Israel - English - Ministry of Health

organon pharma israel ltd., israel - montelukast as sodium - chewable tablets - montelukast as sodium 5 mg - montelukast - montelukast - singulair 5 mg is indicated in adult and pediatric patients 6 years of age and older for the prophylaxis and chronic treatment of asthma including prevention of daytime and nighttime symptoms of the treatment of aspirin-sensitive asthmatic patients and the prevention of exercise-induced bronchoconstriction. singulair is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma. singulair and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability. singulair is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.because the benefits of singulair may not outweigh the risk of neuropsychiatric symptoms in patients with seasonal rhinitis [see warnings and precautions (5.1)], reserve use for patients who have an intolerance to alternative therapies.

Israel - English - Ministry of Health

cts chemical industries ltd, israel - montelukast as sodium - chewable tablets - montelukast as sodium 5 mg - montelukast - montelukast - montair 5 mg is indicated in adult and pediatric patients 6 years of age and older for the prophylaxis and chronic treatment of asthma, including prevention of daytime and nighttime symptoms, the treatment of aspirin-sensitive asthmatic patients, and the prevention of exercise-induced bronchoconstriction.montair 5 mg is effective alone or in combination with other agents used in the maintenance treatment of chronic asthma.montair 5 mg and inhaled corticosteroids may be used concomitantly with additive effects to control asthma or to reduce the inhaled corticosteroid dose while maintaining clinical stability.montair 5 mg is indicated for the relief of symptoms of seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

fair-med healthcare australia pty ltd - montelukast sodium -